Drug Trial Radar · NCT00770133
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
Last checked: Nov 19, 2026Latest source record: Oct 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141
Actual
Start
Feb 2010
Primary completion
Apr 2010
Study completion Jun 2010
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.
Conditions
- Allergic Conjunctivitis
Interventions
Ketotifen/naphazolineDrug
One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.
NaphazolineDrug
One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
KetotifenDrug
One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
VehicleDrug
One drop of vehicle ophthalmic solution at visit 3 and visit 4.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular ItchingTime frame: 3, 5, and 7 minutes post challenge at 14 days
- Conjunctival RednessTime frame: 7, 15, and 20 minutes post challenge at 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ophthalmic Research Consultants, Inc.
North Andover, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.